Company type | Public |
---|---|
Nasdaq:
CLBS Russell Microcap Index component | |
Industry | Biopharmaceuticals |
Headquarters |
Basking Ridge,
New Jersey
[1], United States |
Key people | David J. Mazzo ( CEO) |
Website |
caladrius |
Caladrius Biosciences is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease. [2]
Founded in 1980, [3] the company was formerly known as Corniche Group Inc, Phase III Medical Inc, [4] and NeoStem, Inc., it adopted its current name in 2015. [3]
In 2022, Caladrius and Cend Therapeutics merged to form Lisata Therapeutics. [5]
In 2012 it started a randomized, controlled, double-blind phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow-derived cell therapy enriched for CD34+ cells, for marked reduction in left ventricular function following acute myocardial infarction. [6]
The published study results showed no evidence of benefit from pre-specified endpoints, though there appeared to be evidence suggesting possible dose-related benefit in post-hoc analysis from a subset of patients. [7]
{{
cite web}}
: |first1=
has generic name (
help)